Glioma pp 187-200 | Cite as

Dendritic Cell Vaccines

  • Ryuya YamanakaEmail author
  • Koji Kajiwara
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 746)


Despite progress in brain tumor therapy, the prognosis of malignant glioma patients remains dismal. Among the new treatments currently being investigated, immunotherapy is theoretically very attractive since it offers the potential for high tumor-specific cytotoxicity. Increasing numbers of reports demonstrate that systemic immunotherapy using dendritic cells is capable of inducing an antiglioma response. Therefore, dendritic cell-based immunotherapy could be a new treatment modality for patients with glioma. In this chapter, we will discuss the implications of these findings for glioma therapy, reviewing current literature on dendritic cell-based glioma immunotherapy. We will overview the role of dendritic cells in immunobiology, the central nervous system and tumor immunology, before outlining dendritic cell therapy results in clinical trials and future directions. Dendritic cell-based immunotherapy strategies appear promising as an approach to successfully induce an antitumor immune response in patients with glioma, where it seems to be safe and without major side effects. The development of methods for manipulating dendritic cells for the purpose of vaccination will enhance the clinical usefulness of these cells for biotherapy. Its efficacy should be further determined in randomized, controlled clinical trials.


Dendritic Cell Major Histocompatibility Complex Class Malignant Glioma Tumor Lysate Antitumor Immune Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony-stimulating factor stimulates potent, specific and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90:3539–3543.PubMedCrossRefGoogle Scholar
  2. 2.
    Parney IF, Hao C, Petruk KC. Glioma immunology and immunotherapy. Neurosurgery 2000; 46:778–791.PubMedGoogle Scholar
  3. 3.
    Sampson JH, Archer GE, Ashley DM et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the “immunologically privileged” central nervous system. Proc Natl Acad Sci USA 1996; 93:10399–10404.PubMedCrossRefGoogle Scholar
  4. 4.
    Soling A, Rainov NG. Dendritic cell therapy of primary brain tumors. Mol Med 2001; 7:659–667.PubMedGoogle Scholar
  5. 5.
    Medawar PB. Immunity to homologous grafted skin: III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue and to the anterior chamber of the eye. Br J Exp Pathol 1948; 29:58–69.PubMedGoogle Scholar
  6. 6.
    Satoh J, Lee YB, Kim SU. T-cell costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture. Brain Res 1995; 704:92–99.PubMedCrossRefGoogle Scholar
  7. 7.
    Constam DB, Philipp J, Malipiero UV et al. Differential expression of transforming growth factor-beta 1,-beta 2 and-beta 3 by glioblastoma cells, astrocytes and microglia. J Immunol 1992; 148:1404–1410.PubMedGoogle Scholar
  8. 8.
    Gabrilovich DI, Ishida T, Nadaf S et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999; 5:2963–2970.PubMedGoogle Scholar
  9. 9.
    Chen Q, Daniel V, Maher DW et al. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994; 56:755–760.PubMedCrossRefGoogle Scholar
  10. 10.
    Sonabend AM, Rolle CE, Lesniak MS. The role of regulatory T-cells in malignant glioma. Anticancer Res 2008; 28:1143–1150.PubMedGoogle Scholar
  11. 11.
    Morioka J, Kajiwara K, Yoshikawa K et al. Vaccine therapy for murine glioma using tumor cells genetically modified to express B7.1. Neurosurgery 2004; 54:182–190.PubMedCrossRefGoogle Scholar
  12. 12.
    Amano T, Kajiwara K, Yoshikawa K et al. Anti-tumor effects of vaccination with dendritic cells transfected with modified RHAMM (receptor for hyaluronan-mediated motility) mRNA for mice glioma. J Neurosurg 2007; 106:638–645.PubMedCrossRefGoogle Scholar
  13. 13.
    Heimberger AB, Crotty LE, Archer GE et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 2000; 103:16–25.PubMedCrossRefGoogle Scholar
  14. 14.
    Liau LM, Black KL, Prins RM et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999; 90:1115–1124.PubMedCrossRefGoogle Scholar
  15. 15.
    Yamanaka R, Zullo SA, Tanaka R et al. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg 2001; 94:474–481.PubMedCrossRefGoogle Scholar
  16. 16.
    Constant S, Sant’Angelo D, Pasqualini T et al. Peptide and protein antigens require distinct antigen-presenting cell subsets for the priming of CD4+ T-cells. J Immunol 1995; 154:4915–4923.PubMedGoogle Scholar
  17. 17.
    Levin D, Constant S, Pasqualini T et al. Role of dendritic cells in the priming of CD4+ T-lymphocytes to peptide antigen in vivo. J Immunol 1993; 151:6742–6750.PubMedGoogle Scholar
  18. 18.
    Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9:271–296.PubMedCrossRefGoogle Scholar
  19. 19.
    Steinman RM, Pack M, Inaba K. Dendritic cells in the T-cell areas of lymphoid organs. Immunol Rev 1997; 156:25–37.PubMedCrossRefGoogle Scholar
  20. 20.
    Reis e Sousa C, Stahl PD, Austyn JM. Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med 1993; 178:509–519.Google Scholar
  21. 21.
    Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767–811.PubMedCrossRefGoogle Scholar
  22. 22.
    Steinman RM, Turley S, Mellman I et al. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000; 191:411–416.PubMedCrossRefGoogle Scholar
  23. 23.
    Toes RE, Ossendorp F, Offringa R et al. CD4 T-cells and their role in antitumor immune responses. J Exp Med 1999; 189:753–756.PubMedCrossRefGoogle Scholar
  24. 24.
    Marzo AL, Kinnear BF, Lake RA et al. Tumor-specific CD4(+) T-cells have a major “Post-Licensing” role in CTL mediated anti-tumor immunity. J Immunol 2000; 165:6047–6055.PubMedGoogle Scholar
  25. 25.
    Lipscomb MF, Masten BJ. Dendritic cells: immune regulators in health and disease. Physiol Rev 2002; 82:97–130.PubMedGoogle Scholar
  26. 26.
    Rowland LP. Blood-brain barrier, cerebrospinal fluid, brain edema and hydrocephalus. In: Kanel ER, Schwartz JH eds. Principles of Neuroscience. Amsterdam, Elsevier, 1985:837–844.Google Scholar
  27. 27.
    Cserr HF, Knopf PM. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today 1992; 13:507–512.PubMedCrossRefGoogle Scholar
  28. 28.
    Joo F. Insight into the regulation by second messenger molecules of the permeability of the blood-brain barrier. Microsc Res Tech 1994; 27:507–515.PubMedCrossRefGoogle Scholar
  29. 29.
    Gourmala NG, Buttini M, Limonta S et al. Differential and time-dependent expression of monocyte chemoattractant protein-1 mRNA by astrocytes and macrophages in rat brain: effects of ischemia and peripheral lipopolysaccharide administration. J Neuroimmunol 1997; 74:35–44.PubMedCrossRefGoogle Scholar
  30. 30.
    Miyagishi R, Kikuchi S, Takayama C et al. Identification of cell types producing RANTES, MIP-1 alpha and MIP-1 beta in rat experimental autoimmune encephalomyelitis by in situ hybridization. J Neuroimmunol 1997; 77:17–26.PubMedCrossRefGoogle Scholar
  31. 31.
    Mesri M, Liversidge J, Forrester JV. ICAM-1/LFA-1 interactions in T-lymphocyte activation and adhesion to cells of the blood retina barrier in the rat. Immunology 1994; 83:52–57.PubMedGoogle Scholar
  32. 32.
    Sedgwick JD, Hickey WF. Antigen presentation in the central nervous system. In: Keane RW, Hickey WF eds. Immunology of the Nervous System. Oxford: Oxford University Press, 1997:364–418.Google Scholar
  33. 33.
    McMenamin PG, Forrester JV. Dendritic cells in the central nervous system and eye and their associated supporting tissues. In: Lotze MT, Thomson AW eds. Dendritic cells: Biology and Clinical Applications. San Diego: Academic press, 1999:205–248.Google Scholar
  34. 34.
    Serot JM, Foliguet B, Bene MC et al. Ultrastructural and immunohistological evidence for dendritic-like cells within human choroid plexus epithelium. Neuroreport 1997; 8:1995–1998.PubMedCrossRefGoogle Scholar
  35. 35.
    Matyszak MK, Perry VH. The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system. Neuroscience 1996; 74:599–608.PubMedCrossRefGoogle Scholar
  36. 36.
    Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18:245–273.PubMedCrossRefGoogle Scholar
  37. 37.
    Celluzzi CM, Mayordomo JI, Storkus WJ et al. Peptide-pulsed dendritic cells induce antigen-specific CTL mediated protective tumor immunity. J Exp Med 1996; 183:283–287.PubMedCrossRefGoogle Scholar
  38. 38.
    Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1:1297–1302.PubMedCrossRefGoogle Scholar
  39. 39.
    Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T-lymphocytes. J Exp Med 1995; 182:255–260.PubMedCrossRefGoogle Scholar
  40. 40.
    Ashley DM, Faiola B, Nair S et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186:1177–1182.PubMedCrossRefGoogle Scholar
  41. 41.
    Boczkowski D, Nair SK, Snyder D et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184:465–472.PubMedCrossRefGoogle Scholar
  42. 42.
    Aoki H, Mizuno M, Natsume A et al. Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T-lymphocytes in mouse brain tumor. Cancer Immunol Immunother 2001; 50:463–468.PubMedCrossRefGoogle Scholar
  43. 43.
    Gong J, Chen D, Kashiwaba M et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3:558–561.PubMedCrossRefGoogle Scholar
  44. 44.
    Gong J, Avigan D, Chen D et al. Activation of antitumor cytotoxic T-lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 2000; 97:2715–2718.PubMedCrossRefGoogle Scholar
  45. 45.
    Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T-cells in vivo in humans. Blood 2002; 100:174–177.PubMedCrossRefGoogle Scholar
  46. 46.
    Wakkach A, Fournier N, Brun V et al. Characterization of dendritic cells that induce tolerance and T-regulatory 1 cell differentiation in vivo. Immunity 2003; 18:605–617.PubMedCrossRefGoogle Scholar
  47. 47.
    Bax M, García-Vallejo JJ, Jang-Lee J et al. Dendritic cell maturation results in pronounced changes in glycan expression affecting recognition by siglecs and galectins. J Immunol 2007; 179:8216–8224.PubMedGoogle Scholar
  48. 48.
    Dietz AB, Bulur PA, Knutson GJ et al. Maturation of human monocyte-derived dendritic cells studied by microarray hybridization. Biochem Biophys Res Commun 2000; 275:731–738.PubMedCrossRefGoogle Scholar
  49. 49.
    Barratt-Boyes SM, Zimmer MI, Harshyne LA et al. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J Immunol 2000; 164:2487–2495.PubMedGoogle Scholar
  50. 50.
    de Vries IJ, Lesterhuis WJ, Scharenborg NM et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003; 9:5091–5100.PubMedGoogle Scholar
  51. 51.
    Yu JS, Wheeler CJ, Zeltzer PM et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61:842–847.PubMedGoogle Scholar
  52. 52.
    Liau LM, Prins RM, Kiertscher SM et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005; 11:5515–5525.PubMedCrossRefGoogle Scholar
  53. 53.
    Yu JS, Liu G, Ying H et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64:4973–4979.PubMedCrossRefGoogle Scholar
  54. 54.
    Rutkowski S, De Vleeschouwer S, Kaempgen E et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 2004; 91:1656–1662.PubMedGoogle Scholar
  55. 55.
    Liau LM, Prins RM, Odesa SK et al. Dendritic cell vaccination in combination with TLR-7 agonist, imiquiod following radio-chemotherapy for newly diagnosed glioblastoma. Proc Am Soc Clin Oncol 2007; 25:2021.Google Scholar
  56. 56.
    Kikuchi T, Akasaki Y, Irie M et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 2001; 50:337–344.PubMedCrossRefGoogle Scholar
  57. 57.
    Kikuchi T, Akasaki Y, Abe T et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004; 27:452–459.PubMedCrossRefGoogle Scholar
  58. 58.
    Yamanaka R, Abe T, Yajima N et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 2003; 89:1172–1179.PubMedCrossRefGoogle Scholar
  59. 59.
    Yamanaka R, Homma J, Yajima N et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II Trial. Clin Cancer Res 2005; 11:4160–4167.PubMedCrossRefGoogle Scholar
  60. 60.
    Wheeler CJ, Black KL, Liu G et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 2008; 68:5955–5964.PubMedCrossRefGoogle Scholar
  61. 61.
    De Vleeschouwer S, Fieuws S, Rutkowski S et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008; 14:3098–3104.PubMedCrossRefGoogle Scholar
  62. 62.
    Weiner GJ, Liu HM, Wooldridge JE et al. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997; 94:10833–10837.PubMedCrossRefGoogle Scholar
  63. 63.
    Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation and maturation of human dendritic cells. Proc Natl Acad Sci USA 1999; 96:9305–9310.PubMedCrossRefGoogle Scholar
  64. 64.
    Grabbe S, Kämpgen E, Schuler G. Dendritic cells: multi-lineal and multi functional. Immunol Today 2000; 21:431–433.PubMedCrossRefGoogle Scholar
  65. 65.
    Steiner HH, Bonsanto MM, Beckhove P et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety and clinical benefit. J Clin Oncol 2004; 22:4272–4781.PubMedCrossRefGoogle Scholar
  66. 66.
    Knutson KL, Disis ML. Tumor antigen-specific T-helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54:721–728.PubMedCrossRefGoogle Scholar
  67. 67.
    Arthur JF, Butterfield LH, Roth MD et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997; 4:17–25.PubMedGoogle Scholar
  68. 68.
    Henderson RA, Nimgaonkar MT, Watkins SC et al. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res 1996; 56:3763–3770.PubMedGoogle Scholar
  69. 69.
    Reeves ME, Royal RE, Lam JS et al. Retroviral transduction of human dendritic cells with a tumor associated antigen gene. Cancer Res 1996; 56:5672–5677.PubMedGoogle Scholar
  70. 70.
    Szabolcs P, Gallardo HF, Ciocon DH et al. Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. Blood 1997; 90:2160–2167.PubMedGoogle Scholar
  71. 71.
    Facoetti A, Nano R, Zelini P et al. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res 2005; 11(23):8304–8311.PubMedCrossRefGoogle Scholar
  72. 72.
    Liu G, Akasaki Y, Khong HT et al. Cytotoxic T-cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene 2005; 24:5226–5234.PubMedCrossRefGoogle Scholar
  73. 73.
    Liu G, Black KL, Yu JS. Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. Expert Rev Vaccines 2006; 5:233–247.PubMedCrossRefGoogle Scholar
  74. 74.
    Wheeler CJ, Das A, Liu G et al. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004; 10:5316–5326.PubMedCrossRefGoogle Scholar
  75. 75.
    Grauer OM, Nierkens S, Bennink E et al. CD4+FoxP3+ regulatory T-cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007; 121(1):95–105.PubMedCrossRefGoogle Scholar
  76. 76.
    Yamanaka R. Cellular and peptide based immunotherapeutic approaches for glioma. Trends Mol Med 2008; 14:228–235.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2012

Authors and Affiliations

  1. 1.Kyoto Prefectural University of MedicineKyoto
  2. 2.Yamaguchi University School of MedicineUbeJapan

Personalised recommendations